Abacavir + LamivudineThird Party Manufacturing in India

The combination of Abacavir and Lamivudine works by dual inhibition of the HIV-1 reverse transcriptase enzyme.

Once inside the host cells, both molecules are metabolized into their active triphosphate forms. These active metabolites compete with natural nucleosides to be incorporated into the growing viral DNA chain. Once incorporated, they cause premature DNA chain termination, halting the replication of the viral genome.

Unlike single-agent therapies, this combination provides a synergistic antiviral effect with a higher genetic barrier to resistance. It is highly effective and well-tolerated for patients as part of a comprehensive antiretroviral regimen.

Therapeutic Uses

Abacavir and Lamivudine combination is prescribed for the treatment of:

• HIV-1 Infection: Used as a backbone component in combination antiretroviral therapy (cART) for adults and adolescents.
• Viral Load Reduction: Effectively reduces the amount of HIV in the blood to undetectable levels.
• Immune System Preservation: Helps restore and maintain CD4+ cell counts, preventing opportunistic infections.

Why Manufacturers Choose Abacavir + Lamivudine

As a crucial first-line and maintenance antiretroviral backbone, the combination of Abacavir and Lamivudine enjoys significant global and domestic demand. Its fixed-dose combination ensures better patient adherence compared to separate pills.

This makes Abacavir + Lamivudine one of the most sought-after molecules for third party manufacturing in India, with consistent demand from government tenders, institutional supplies, and export-oriented companies targeting the HIV treatment market.